TIDMSAR
RNS Number : 8299S
Sareum Holdings PLC
08 November 2023
Sareum Holdings PLC
("Sareum" or the "Company")
Director Dealings
Cambridge, UK, 8 November 2023 - Sareum Holdings plc (AIM: SAR),
a biotechnology company developing next generation kinase
inhibitors for autoimmune disease and cancer, announces the
following share transactions carried out by Directors.
As announced on 2 November 2023, Dr Tim Mitchell, Chief
Executive Officer, and Dr John Reader, Chief Scientific Officer,
each exercised options over 95,040 ordinary shares of 1.25 pence
each in the Company (the "Options Exercise"), at an exercise price
of 30 pence per ordinary share.
Of those shares received pursuant to the Options Exercise, Dr
Mitchell and Dr Reader have retained 23,040 and 44,614 ordinary
shares, respectively, following the sale of 72,000 and 50,426
ordinary shares, respectively, at a price of 56.8 pence per
ordinary share (the "Share Sales"). The Share Sales were undertaken
partly in order to compensate for the cost and tax liabilities
arising from the Options Exercise.
Following the Options Exercise and Share Sales, Dr Mitchell's
and Dr Reader's resultant interests in the Company will be as
follows:
Director/ Number of Number of Sale Resultant Percentage
PDMR shares purchased shares sold price total number of issued
pursuant to pursuant of ordinary share capital
the Options to Sale Shares shares held
Exercise in the Company
T im Mitchell
(1) 95,040 72,000 56.8p 1,032,561 1.47%
------------------ ---------------- -------- ---------------- ---------------
J ohn Reader
(2) 95,040 50,426 56.8p 1,077,111 1.53%
------------------ ---------------- -------- ---------------- ---------------
(1) - Included within Tim Mitchell's total holding are 200,000
ordinary shares held by his spouse.
(2) - Included withing John Reader's total holding are 66,666
ordinary shares held by his spouse.
For further information, please contact:
Sareum Holdings plc
Tim Mitchell, CEO 01223 497700
Lauren Williams, Head of Investor Relations ir@sareum.co.uk
Strand Hanson Limited (Nominated Adviser)
James Dance / James Bellman 020 7409 3494
Peel Hunt LLP (Joint Corporate Broker)
James Steel / Patrick Birkholm 020 7418 8900
Hybridan LLP (Joint Corporate Broker)
Claire Noyce
020 3764 2341
ICR Consilium (Financial PR)
Jessica Hodgson / Davide Salvi / Stella
Lempidaki 020 3709 5700
PDMR Notification Forms
The information set out below is provided in accordance with the
requirements of Article 19(3) of the EU Market Abuse Regulation No
596/2014.
1. Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Tim Mitchell
-------------------------------- --------------------------------------------
2. Reason for the Notification
------------------------------------------------------------------------------
a) Position/status Chief Executive Officer
-------------------------------- --------------------------------------------
b) Initial notification/amendment Initial notification
-------------------------------- --------------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
------------------------------------------------------------------------------
a) Name SAREUM HOLDINGS PLC
-------------------------------- --------------------------------------------
b) LEI 213800PKERN2DY8FFM72
-------------------------------- --------------------------------------------
4. Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv)each place where transactions have
been conducted
------------------------------------------------------------------------------
a) Description of the Financial Ordinary shares of 1.25p each in the
instrument, type of instrument share capital of Sareum Holdings plc
-------------------------------- --------------------------------------------
Identification code ISIN for Ordinary Shares: GB00B02RFS12
-------------------------------- --------------------------------------------
b) Nature of the Transaction Sale of ordinary shares
-------------------------------- --------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
56.8p 72,000 sold
-----------------------
-------------------------------- --------------------------------------------
d) Aggregated information Price(s) Volume(s)
* Aggregated volume 56.8p 72,000 sold
-----------------------
* Price
-------------------------------- --------------------------------------------
e) Date of the transaction 7 November 2023
-------------------------------- --------------------------------------------
f) Place of the transaction London Stock Exchange (AIM)
-------------------------------- --------------------------------------------
1. Details of the person discharging managerial responsibilities
/ person closely associated
a) Name John Reader
-------------------------------- --------------------------------------------
2. Reason for the Notification
------------------------------------------------------------------------------
a) Position/status Chief Scientific Officer
-------------------------------- --------------------------------------------
b) Initial notification/amendment Initial notification
-------------------------------- --------------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
------------------------------------------------------------------------------
a) Name SAREUM HOLDINGS PLC
-------------------------------- --------------------------------------------
b) LEI 213800PKERN2DY8FFM72
-------------------------------- --------------------------------------------
4. Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv)each place where transactions have
been conducted
------------------------------------------------------------------------------
a) Description of the Financial Ordinary shares of 0.025p each in
instrument, type of instrument the share capital of Sareum Holdings
plc
-------------------------------- --------------------------------------------
Identification code ISIN for Ordinary Shares: GB00B02RFS12
-------------------------------- --------------------------------------------
b) Nature of the Transaction Sale of ordinary shares
-------------------------------- --------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
56.8p 50,426 sold
-----------------------
-------------------------------- --------------------------------------------
d) Aggregated information Price(s) Volume(s)
* Aggregated volume 56.8p 50,426 sold
-----------------------
* Price
-------------------------------- --------------------------------------------
e) Date of the transaction 7 November 2023
-------------------------------- --------------------------------------------
f) Place of the transaction London Stock Exchange (AIM)
-------------------------------- --------------------------------------------
About Sareum
Sareum Holdings (AIM:SAR) is a clinical-stage biotechnology
company developing next generation kinase inhibitors for autoimmune
disease and cancer.
The Company is focused on developing next generation small
molecules which modify the activity of the JAK kinase family and
have best-in-class potential. Its lead candidate, SDC-1801,
simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential
treatment for a range of autoimmune diseases and has entered Phase
1a/b clinical development with an initial focus on psoriasis.
Sareum has an economic interest in SRA737, a clinical-stage Chk1
inhibitor which it originally developed in collaboration with
several Cancer Research UK-related organisations. SRA737 has shown
promising safety and efficacy in two Phase 1/2 clinical trials.
Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a
potential application for cancer immunotherapy.
Sareum Holdings plc is based in Cambridge, UK, and is listed on
the AIM market of the London Stock Exchange, trading under the
ticker SAR. For further information, please visit the Company's
website at www.sareum.com
- Ends -
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHBSBDBCUGDGXI
(END) Dow Jones Newswires
November 08, 2023 10:03 ET (15:03 GMT)
Sareum (LSE:SAR)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Sareum (LSE:SAR)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024
